ExpreS2ion Biotech Holding AB
STO:EXPRS2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EXPRS2's latest stock split occurred on Oct 30, 2024
The company executed a 1-for-40 stock split, meaning that for every 40 shares held, investors received 1 new share.
Before the split, EXPRS2 traded at 0.848 per share. Afterward, the share price was about 31.4.
The adjusted shares began trading on Oct 30, 2024. This was the only stock split in EXPRS2's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Mar 20, 2026
|
S
|
Sonid Inc
KOSDAQ:060230
|
5-for-1
x5
|
1842 368.4 KRW | 478 478 KRW |
|
Mar 20, 2026
|
D
|
DELISTED SECURITIES
NYSE:IRE
|
1-for-4
/4
|
20.28 20.28 USD | 19.94 19.94 USD |
|
Mar 20, 2026
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
4-for-1
x4
|
1825 456.25 INR | 441.1 441.1 INR |
|
Mar 20, 2026
|
T
|
TJ Media Co Ltd
KOSDAQ:032540
|
3-for-2
x1.5
|
6170.0029 4113.3353 KRW | 4020 4020 KRW |
|
Mar 20, 2026
|
T
|
Tianci International Inc
OTC:CIIT
|
1-for-7
/7
|
0.27 1.89 USD | 1.72 1.72 USD |
METROPOLIS
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
